TGTX: TG Therapeutics, Inc. Company Profile & Statistics

About

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Info & Links

CEO

Michael S. Weiss

Headquarters

3020 CARRINGTON MILL BLVD, SUITE 475
MORRISVILLE, NY 27560, UNITED STATES

Auditor

KPMG LLP

Share holders

204

Employees

338

TG Therapeutics, Inc. Statistics

Valuation Measures

Market Capitalization²

5.77B

Enterprise Value

5.83B

Enterprise Value/EBITDA(ttm)

156.69

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

18.19

Price to Book(mrq)

24.93

Price to Cash(ytd)

353.90

Profitability

Gross Margin(ttm)

88.69%

Operating Margin(ttm)

-5.42%

Profit Margin(ttm)

4.67%

Return on Equity(ttm)

-8.32%

Return on Invested Capital(ttm)

4.25%

Return on Assets(ttm)

-3.40%

Income Statement

Revenue(ttm)

329.00M

Revenue Per Share(ttm)

2.09

Gross Profit(ttm)

290.52M

EBITDA(ttm)³

37.22M

Net Income Available to Common(ttm)

23.38M

Diluted EPS(ttm)

-0.10

Share Statistics

Beta (5Y Monthly)

2.26

52-Week Change

157.31%

S&P 500 52-Week Change

-2.47%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

157.07M

Dividend Yield

0.00%

Float⁴

139.32M

% Held by Insiders

10.50%

% Held by Institutions

58.58%

Balance Sheet

Total Cash(mrq)

311.00M

Total Cash Per Share(mrq)

1.98

Total Debt(mrq)

244.43M

Total Debt/Equity(mrq)

109.92%

Current Ratio(mrq)

6.25%

Quick Ratio(mrq)

3.91%

Book Value Per Share(mrq)

1.43

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.25

Free Cash Flow(ytd)

-40.56M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

TGTX

TG Therapeutics, Inc.

TG Therapeutics, Inc. Profile